| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |